The Medical Letter on Drugs and Therapeutics
Rufinamide (Banzel) for Epilepsy
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Rufinamide (Banzel – Eisai), a triazole derivative structurally unrelated to other marketed antiepileptic drugs (AEDs), has been approved by the FDA for treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients ≥4 years old.

LENNOX-GASTAUT SYNDROME — Lennox-Gastaut syndrome is a severe form of childhood epilepsy characterized by multiple types of seizures, often refractory to any treatment, and mental retardation. Most pediatric neurologists consider valproic acid (Depakene, and others) the first-line treatment for LGS,1,2 but only topiramate (Topamax), lamotrigine (Lamictal, and others) and felbamate (Felbatol) are FDA-approved for use in this disorder.

CLINICAL STUDIES — Approval of rufinamide for use in LGS was based on a randomized, double-blind, placebo-controlled, 12-week add-on trial in 138 ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Rufinamide (Banzel) for Epilepsy
Article code: 1307b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian